

### AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A pharmaceutical preparation comprising effective amounts of a fibrinolytic agent and an antioxidant, wherein said pharmaceutical preparation is in the form of an orally administerable tablet or capsule.

2. **(Original)** The composition of Claim 1, wherein the fibrinolytic agent is an enzyme selected from the group consisting of nattokinase, urokinase, subtilisin, and plasmin.

3. **(Original)** The composition of Claim 1, wherein the antioxidant is selected from the group consisting of: vitamin C, vitamin E, a catechin, a carotenoid, a flavonoid, coenzyme Q10 (ubiquinone), an isoflavone, a phenylpropanoid, a polyphenol, a tocopherol, alpha tocopherol, selenium, magnesium,  $\alpha$ -lipoic acid, TBHQ, BHA, BHT, a tocotrienol, ascorbic acid, resveratrol, a pine bark extract, an oleoresin, rosemary extract, tea extract, grape seed extract, and an antioxidant extract from fruit skin or from a seed.

4. **(Original)** A pharmaceutical preparation comprising effective amounts of pine bark extract and nattokinase.

5. **(Original)** The pharmaceutical preparation of Claim 4, wherein said pine bark extract is prepared from French Maritime Pine, *Pinus maritima*.

6. **(Currently amended)** A method for decreasing or preventing swelling of the lower extremities, edema, pulmonary embolism, or thrombosis, comprising:

identifying a patient in need of decreasing or preventing swelling of the lower extremities, edema, pulmonary embolism, or thrombosis; and

administering to said patient a pharmaceutical preparation comprising—a fibrinolytic agent and an antioxidant the pharmaceutical composition of Claim 1.

7. **(Original)** The method of Claim 6, wherein said swelling of the lower extremities, edema, pulmonary embolism, or thrombosis results from confinement or enforced inactivity.

8. **(Original)** The method of Claim 6, wherein said fibrinolytic agent is an enzyme.

9. **(Original)** The method of Claim 8, wherein said enzyme is selected from the group consisting of urokinase, subtilisin, and plasmin.

10. **(Original)** The method of Claim 8, wherein said enzyme is nattokinase.

11. **(Original)** The method of Claim 6, wherein said antioxidant is selected from the group consisting of: vitamin C, vitamin E, a catechin, a carotenoid, a flavonoid, coenzyme Q10 (ubiquinone), an isoflavone, a phenylpropanoid, a polyphenol, a tocopherol, alpha tocopherol, selenium, magnesium,  $\alpha$ -lipoic acid, TBHQ, BHA, BHT, a tocotrienol, ascorbic acid, resveratrol, an oleoresin, rosemary extract, tea extract, grape seed extract, and an antioxidant extract from fruit skin or from a seed.

12. **(Original)** The method of Claim 6, wherein said antioxidant is pine bark extract.

13. **(Original)** The method of Claim 12, wherein said pine bark is from French maritime pine (*Pinus maritima*).

14. **(Original)** The method of Claim 12, wherein said extract is an aqueous extract.

15. **(Original)** The method of Claim 12, wherein said extract comprises at least one component selected from the group consisting of: bioflavonoid, catechin, epicatechin, taxifolin, oligomeric proanthocyanidin, phenolic fruit acid, ferulic acid, and caffeic acid.

16. **(Original)** The method of Claim 7, wherein said confinement or enforced inactivity is due to one or more selected from the group consisting of: airline flight, bus travel, car travel, or train travel.

17. **(Original)** The method of Claim 16, wherein said confinement or enforced inactivity is due to an airline flight.

18. **(Original)** The method of Claim 17, wherein said airline flight is of a duration of greater than 6 hours.

19. **(New)** The pharmaceutical preparation of Claim 1, wherein said tablet is a coated tablet.

20. **(New)** The pharmaceutical preparation of Claim 4, wherein said pine bark extract is present at a range of from about 20 to 2,000 mg per tablet or capsule.

21. **(New)** The pharmaceutical preparation of Claim 4, wherein said nattokinase is substantially purified.

22. **(New)** The pharmaceutical preparation of Claim 4, wherein said nattokinase is present at an amount having from about 50 to about 3,000 fibrinolytic units per tablet or capsule.

**Appl. No.** : **10/647,131**  
**Filed** : **August 22, 2003**

23. (New) The pharmaceutical preparation of Claim 21, wherein said substantially purified nattokinase is present at an amount having from about 50 to about 3,000 fibrinolytic units per tablet or capsule, and further wherein said pine bark extract is present at a range of from about 20 to 2,000 mg per tablet or capsule.

24. (New) The pharmaceutical preparation of Claim 1, wherein the fibrinolytic agent plus antioxidant in each of said tablet or capsule weighs from about 0.05 mg/kg of patient body weight to about 1,000 mg/kg of patient body weight.

25. (New) The pharmaceutical preparation of Claim 1, further comprising at least one pharmaceutical excipient.